Interaction of insulin-like growth factor (IGF)-I and -II with IGF binding protein-2: mapping the binding surfaces by nuclear magnetic resonance.

The interaction of IGF binding protein-2 (IGFBP-2) with IGF-I and -II has been investigated in solution using nuclear magnetic resonance (NMR) spectroscopy. Chemical shift perturbations in 15N- and 2H/15N-labelled IGF-I or -II upon binding to unlabelled thioredoxin-tagged bovine IGFBP-2 (Trx(1-279)IGFBP-2) have been monitored to identify residues involved directly in the binding interaction as well as any affected by conformational changes associated with the interaction. A key step in obtaining high-quality spectra of the complexes was the use of transverse relaxation optimised spectroscopy (TROSY) methods with partially deuterated ligands. Indeed, because the effects of conformational averaging and aggregation are eliminated in IGF-I and -II bound to IGFBP-2, the spectra of the complexes are actually superior to those of the free ligands. Comparison of our results with the crystal structure of the complex between IGF-I and an N-terminal fragment of IGFBP-5 allowed identification of those residues perturbed by the C-domain of IGFBP-2. Other perturbations, such as those of Gly 19 and Asp 20 of IGF-I (and the corresponding residues in IGF-II) - which are located in a reverse turn linking N-domain and C-domain interactive surfaces - are due to local conformational changes in the IGF-I and -II. Our results confirm that the C-domain of IGFBP-2 plays a key role in binding regions of IGF-I and -II that are also involved in binding to the type-1 IGF receptor and thereby blocking ligand binding to this receptor.

[1]  A. Paisley,et al.  Medical treatment in acromegaly. , 2003, Current opinion in pharmacology.

[2]  P. Calvert.  NMR of macromolecules , 1977, Nature.

[3]  S. Koide,et al.  Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. , 2000, Journal of molecular biology.

[4]  J. Wallace,et al.  The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[5]  J. Wallace,et al.  Linkers for improved cleavage of fusion proteins with an engineered α‐lytic protease , 2001 .

[6]  Y. Kyōgoku,et al.  Three-dimensional solution structure of a disulfide bond isomer of the human insulin-like growth factor-I. , 2000, The journal of peptide research : official journal of the American Peptide Society.

[7]  G. Wider,et al.  TROSY in NMR studies of the structure and function of large biological macromolecules. , 2003, Current opinion in structural biology.

[8]  J. Wallace,et al.  Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II. , 1993, The Biochemical journal.

[9]  Eric Oldfield,et al.  1H, 13C and 15N chemical shift referencing in biomolecular NMR , 1995, Journal of biomolecular NMR.

[10]  R. Norton,et al.  Solution structure of human insulin-like growth factor II. Relationship to receptor and binding protein interactions. , 1995, Journal of molecular biology.

[11]  G. Zhu,et al.  Sensitivity Enhancement in Transverse Relaxation Optimized NMR Spectroscopy. , 1998, Angewandte Chemie.

[12]  M. Bayne,et al.  The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor. , 1990, The Journal of biological chemistry.

[13]  J. Frystyk.  Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. , 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[14]  P. McNamara,et al.  A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide. , 1989, The Biochemical journal.

[15]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[16]  Pnur BnlqN Moonn,et al.  Solution of the Structure , 2007 .

[17]  J Liu,et al.  Crystal structure of human insulin-like growth factor-1: detergent binding inhibits binding protein interactions. , 2001, Biochemistry.

[18]  M. Rechler,et al.  Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. , 1993, The Journal of biological chemistry.

[19]  M. Bayne,et al.  Serum half-life and biological activity of mutants of human insulin-like growth factor I which do not bind to serum binding proteins. , 1988, Endocrinology.

[20]  Gerald Nakamura,et al.  Complex with a phage display-derived peptide provides insight into the function of insulin-like growth factor I. , 2003, Biochemistry.

[21]  M. Rechler,et al.  Recombinant human insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced differentiation of L6A1 myoblasts. , 1994, Endocrinology.

[22]  B. Roth,et al.  Mutants of human insulin-like growth factor II (IGF II). Expression and characterization of truncated IGF II and of two naturally occurring variants. , 1992, European journal of biochemistry.

[23]  Y. Kyōgoku,et al.  Three-dimensional structure of human insulin-like growth factor-I (IGF-I) determined by 1H-NMR and distance geometry. , 2009, International journal of peptide and protein research.

[24]  J. Wallace,et al.  Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins. , 1992, Journal of molecular endocrinology.

[25]  I. Campbell,et al.  Solution structure of human insulin-like growth factor 1: a nuclear magnetic resonance and restrained molecular dynamics study. , 1993, Biochemistry.

[26]  J. Wallace,et al.  BIAcore Analysis of Bovine Insulin-like Growth Factor (IGF)-binding Protein-2 Identifies Major IGF Binding Site Determinants in Both the Amino- and Carboxyl-terminal Domains* , 2001, The Journal of Biological Chemistry.

[27]  M. Jansson,et al.  The Insulin-like Growth Factor (IGF)Binding Protein 1 Binding Epitope on IGF-I Probed by Heteronuclear NMR Spectroscopy and Mutational Analysis* , 1998, The Journal of Biological Chemistry.

[28]  J. Carver,et al.  Secondary structure determination of 15N‐labelled human Long‐[Arg‐3]‐insulin‐like growth factor 1 by multidimensional NMR spectroscopy , 1997, FEBS letters.

[29]  M. Bayne,et al.  Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor. , 1988, The Journal of biological chemistry.

[30]  R. Norton,et al.  C-terminal domain of insulin-like growth factor binding protein-6: structure and interaction with insulin-like growth factor-II , 2004 .

[31]  Hideo Takahashi,et al.  A novel NMR method for determining the interfaces of large protein–protein complexes , 2000, Nature Structural Biology.

[32]  C. Renner,et al.  Structure of the IGF‐binding domain of the insulin‐like growth factor‐binding protein‐5 (IGFBP‐5): implications for IGF and IGF‐I receptor interactions , 1998, The EMBO journal.

[33]  D. Clemmons,et al.  Cloning and sequence determination of bovine insulin‐like growth factor binding protein‐2 (IGFBP‐2): Comparison of its structral and functional properties with IGFBP‐1 , 1992, Journal of cellular biochemistry.

[34]  S. Koide,et al.  NMR identification of epitopes of Lyme disease antigen OspA to monoclonal antibodies. , 1998, Journal of molecular biology.

[35]  M. Weiss,et al.  Comparative 2D NMR studies of human insulin and des-pentapeptide insulin: sequential resonance assignment and implications for protein dynamics and receptor recognition. , 1991, Biochemistry.

[36]  J. Perdue,et al.  The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor. , 1991, The Journal of biological chemistry.

[37]  J. Wallace,et al.  Insulin-like growth factor I and its binding proteins: a study of the binding interface using B-domain analogues. , 1999, Biochemistry.

[38]  D. Clemmons,et al.  Use of mutagenesis to probe IGF-binding protein structure/function relationships. , 2001, Endocrine reviews.

[39]  Vladimir Sklenar,et al.  Gradient-Tailored Water Suppression for 1H-15N HSQC Experiments Optimized to Retain Full Sensitivity , 1993 .

[40]  I. Shimada,et al.  Determination of the interface of a large protein complex by transferred cross-saturation measurements. , 2002, Journal of molecular biology.

[41]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[42]  M. Rechler,et al.  Hybrid molecules containing the B-domain of insulin-like growth factor I are recognized by carrier proteins of the growth factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Zhu,et al.  Gradient and sensitivity enhanced multiple-quantum coherence in heteronuclear multidimensional NMR experiments , 1999, Journal of biomolecular NMR.

[44]  R. Rosenfeld,et al.  Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. , 1993, Endocrinology.

[45]  Y. Kyōgoku,et al.  1H-NMR assignment and secondary structure of human insulin-like growth factor-I (IGF-I) in solution. , 1992, Journal of Biochemistry (Tokyo).

[46]  K Wüthrich,et al.  The program XEASY for computer-supported NMR spectral analysis of biological macromolecules , 1995, Journal of biomolecular NMR.

[47]  R. M. Justice,et al.  Complete sequence-specific 1H NMR assignments for human insulin. , 1990, Biochemistry.

[48]  D. Clemmons,et al.  Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs. , 1992, Endocrinology.

[49]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[50]  R. Riek,et al.  Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  R. Norton,et al.  C-terminal domain of insulin-like growth factor (IGF) binding protein-6: structure and interaction with IGF-II. , 2004, Molecular endocrinology.

[52]  J. Carver,et al.  Solution Structure and Backbone Dynamics of Long-[Arg3]insulin-like Growth Factor-I* , 2000, The Journal of Biological Chemistry.

[53]  D. Kohda,et al.  Solution structure of human insulin‐like growth factor II; recognition sites for receptors and binding proteins. , 1994, The EMBO journal.

[54]  Karolin Luger,et al.  Structural determinants for generating centromeric chromatin , 2004, Nature.

[55]  R. Norton,et al.  Binding site for the C‐domain of insulin‐like growth factor (IGF) binding protein‐6 on IGF‐II; implications for inhibition of IGF actions , 2004, FEBS letters.

[56]  T. Holak,et al.  The interaction of insulin‐like growth factor‐I with the N‐terminal domain of IGFBP‐5 , 2001, The EMBO journal.

[57]  H. Lowman,et al.  Total alanine-scanning mutagenesis of insulin-like growth factor I (IGF-I) identifies differential binding epitopes for IGFBP-1 and IGFBP-3. , 1999, Biochemistry.